Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma

Urology

Volumn 81, Issue 3, 2013, Pages 581-586

  Darwish, Oussama M ^b   Kapur, Payal ^b   Youssef, Ramy F ^b   Bagrodia, Aditya ^b   Belsante, Michael ^b   Alhalabi, Feras ^b   Sagalowsky, Arthur I ^b   Lotan, Yair ^b   Margulis, Vitaly ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84875364330     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.11.030     Document Type: Article

References (30)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. N.K. Janzen, H.L. Kim, and R.A. Figlin Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am 30 2003 843 852
3. B. Ljungberg, F.I. Alamdari, and T. Rasmuson Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy BJU Int 84 1999 405 411
4. J.S. Lam, J.T. Leppert, and R.A. Figlin Surveillance following radical or partial nephrectomy for renal cell carcinoma Curr Urol Rep 6 2005 7 18
5. R.A. Figlin, W.C. Pierce, and R. Kaboo Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor J Urol 158 3 Pt 1 1997 740 745
6. I. Frank, M.L. Blute, and J.C. Cheville An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score J Urol 168 2002 2395 2400
7. A. Zisman, A.J. Pantuck, and F. Dorey Improved prognostication of renal cell carcinoma using an integrated staging system J Clin Oncol 19 2001 1649 1657
8. M.W. Kattan, V. Reuter, and R.J. Motzer A postoperative prognostic nomogram for renal cell carcinoma J Urol 166 2001 63 67
9. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
10. M. Oya Renal cell carcinoma: biological features and rationale for molecular-targeted therapy Keio J Med 58 2009 1 11
11. A.J. Pantuck, G. Zeng, and A.S. Belldegrun Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway Clin Cancer Res 9 2003 4641 4652
12. D.D. Sarbassov, S.M. Ali, and D.M. Sabatini Growing roles for the mTOR pathway Curr Opin Cell Biol 17 2005 596 603
13. H. Azim, H.A. Azim Jr., and B. Escudier Targeting mTOR in cancer: renal cell is just a beginning Target Oncol 5 2010 269 280
14. C. Sourbier, V. Lindner, and H. Lang The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy Cancer Res 66 2006 5130 5142
15. D.M. Sabatini mTOR and cancer: insights into a complex relationship Nat Rev Cancer 6 2006 729 734
16. B.D. Manning, and L.C. Cantley United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling Biochem Soc Trans 31 Pt 3 2003 573 578
17. J.N. Eble World Health Organization: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs 2004 IARC Press Lyon 359
18. S.A. Fuhrman, L.C. Lasky, and C. Limas Prognostic significance of morphologic parameters in renal cell carcinoma Am J Surg Pathol 6 1982 655 663
19. S.B. Edge, D.R. Byrd, and C.C. Compton AJCC Staging Manual 7th ed. 2009 Springer Philadelphia
20. P. Kapur, Y. Lotan, and E. King Primary adenocarcinoma of the urinary bladder: value of cell cycle biomarkers Am J Clin Pathol 135 2011 822 830
21. C.H. Lawrie, E. Ballabio, and E. Soilleux Inter- and intra-observational variability in immunohistochemistry: a multicentre analysis of diffuse large B-cell lymphoma staining Histopathology 61 2012 18 25
22. A. Bagrodia, R.F. Youssef, and P. Kapur Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma Eur Urol 62 2012 e27 e29
23. J.S. Lam, O. Shvarts, and J.T. Leppert Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy J Urol 173 2005 1853 1862
24. M.B. Atkins, D.E. Avigan, and R.M. Bukowski Innovations and challenges in renal cancer: consensus statement from the first international conference Clin Cancer Res 10 18 Pt 2 2004 6277S 6281S
25. H.L. Kim, D. Seligson, and X. Liu Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma J Urol 173 2005 1496 1501
26. L. Schultz, A. Chaux, and R. Albadine Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas Am J Surg Pathol 35 2011 1549 1556
27. A.S. Parker, B.C. Leibovich, and C.M. Lohse Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma Cancer 115 2009 2092 2103
28. V. Margulis, and C.G. Wood Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy? Eur Urol 54 2008 489 492
29. R.L. Divi, Y.P. Dragan, and H.C. Pitot Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen Carcinogenesis 22 2001 1693 1699
30. S. Mohr, G.D. Leikauf, and G. Keith Microarrays as cancer keys: an array of possibilities J Clin Oncol 20 2002 3165 3175